131 related articles for article (PubMed ID: 22616739)
1. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Tong G; Wang JS; Sverdlov O; Huang SP; Slemmon R; Croop R; Castaneda L; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Dockens R
Br J Clin Pharmacol; 2013 Jan; 75(1):136-45. PubMed ID: 22616739
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Dockens R; Wang JS; Castaneda L; Sverdlov O; Huang SP; Slemmon R; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Tong G
Clin Pharmacokinet; 2012 Oct; 51(10):681-93. PubMed ID: 23018531
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Tong G; Wang JS; Sverdlov O; Huang SP; Slemmon R; Croop R; Castaneda L; Gu H; Wong O; Li H; Berman RM; Smith C; Albright CF; Dockens RC
Clin Ther; 2012 Mar; 34(3):654-67. PubMed ID: 22381714
[TBL] [Abstract][Full Text] [Related]
4. Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.
Tong G; Castaneda L; Wang JS; Sverdlov O; Huang SP; Slemmon R; Gu H; Wong O; Li H; Berman RM; Smith C; Albright C; Dockens RC
Clin Drug Investig; 2012 Nov; 32(11):761-9. PubMed ID: 23018285
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Albright CF; Dockens RC; Meredith JE; Olson RE; Slemmon R; Lentz KA; Wang JS; Denton RR; Pilcher G; Rhyne PW; Raybon JJ; Barten DM; Burton C; Toyn JH; Sankaranarayanan S; Polson C; Guss V; White R; Simutis F; Sanderson T; Gillman KW; Starrett JE; Bronson J; Sverdlov O; Huang SP; Castaneda L; Feldman H; Coric V; Zaczek R; Macor JE; Houston J; Berman RM; Tong G
J Pharmacol Exp Ther; 2013 Mar; 344(3):686-95. PubMed ID: 23275065
[TBL] [Abstract][Full Text] [Related]
7. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
Coric V; Salloway S; van Dyck CH; Dubois B; Andreasen N; Brody M; Curtis C; Soininen H; Thein S; Shiovitz T; Pilcher G; Ferris S; Colby S; Kerselaers W; Dockens R; Soares H; Kaplita S; Luo F; Pachai C; Bracoud L; Mintun M; Grill JD; Marek K; Seibyl J; Cedarbaum JM; Albright C; Feldman HH; Berman RM
JAMA Neurol; 2015 Nov; 72(11):1324-33. PubMed ID: 26414022
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical Safety Assessment of the γ-Secretase Inhibitor Avagacestat.
Simutis FJ; Sanderson TP; Pilcher GD; Graziano MJ
Toxicol Sci; 2018 Jun; 163(2):525-542. PubMed ID: 29529279
[TBL] [Abstract][Full Text] [Related]
9. BMS-708,163 targets presenilin and lacks notch-sparing activity.
Crump CJ; Castro SV; Wang F; Pozdnyakov N; Ballard TE; Sisodia SS; Bales KR; Johnson DS; Li YM
Biochemistry; 2012 Sep; 51(37):7209-11. PubMed ID: 22931393
[TBL] [Abstract][Full Text] [Related]
10. Gamma secretase inhibition: Effects on fertility and embryo-fetal development in rats.
Sivaraman L; Sanderson T
Toxicol Appl Pharmacol; 2023 Jun; 469():116512. PubMed ID: 37030625
[TBL] [Abstract][Full Text] [Related]
11. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
Fleisher AS; Raman R; Siemers ER; Becerra L; Clark CM; Dean RA; Farlow MR; Galvin JE; Peskind ER; Quinn JF; Sherzai A; Sowell BB; Aisen PS; Thal LJ
Arch Neurol; 2008 Aug; 65(8):1031-8. PubMed ID: 18695053
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects.
Yu Y; Logovinsky V; Schuck E; Kaplow J; Chang MK; Miyagawa T; Wong N; Ferry J
J Clin Pharmacol; 2014 May; 54(5):528-36. PubMed ID: 24343761
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of carbon-14 and stable isotope labeled Avagacestat: a novel gamma secretase inhibitor for the treatment of Alzheimer's disease.
Burrell RC; Easter JA; Cassidy MP; Gillman KW; Olson RE; Bonacorsi SJ
J Labelled Comp Radiopharm; 2014 Aug; 57(10):600-5. PubMed ID: 25196195
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of γ-Secretase Leads to an Increase in Presenilin-1.
Sogorb-Esteve A; García-Ayllón MS; Llansola M; Felipo V; Blennow K; Sáez-Valero J
Mol Neurobiol; 2018 Jun; 55(6):5047-5058. PubMed ID: 28815510
[TBL] [Abstract][Full Text] [Related]
17. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects.
Patat A; Parks V; Raje S; Plotka A; Chassard D; Le Coz F
Br J Clin Pharmacol; 2009 Mar; 67(3):299-308. PubMed ID: 19523013
[TBL] [Abstract][Full Text] [Related]
19. The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers.
Soares HD; Gasior M; Toyn JH; Wang JS; Hong Q; Berisha F; Furlong MT; Raybon J; Lentz KA; Sweeney F; Zheng N; Akinsanya B; Berman RM; Thompson LA; Olson RE; Morrison J; Drexler DM; Macor JE; Albright CF; Ahlijanian MK; AbuTarif M
J Pharmacol Exp Ther; 2016 Jul; 358(1):138-50. PubMed ID: 27189973
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
